Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

  • Moura, David
  • Peña-Chilet, Maria
  • Cordero Varela, Juan Antonio
  • Alvarez Alegret, Ramiro
  • AGRA PUJOL, CAROLINA
  • Izquierdo, Francisco
  • Romagosa, Cleofé
  • Valverde, Claudia María
Signatura genètica; Biomarcadors predictius; Trabectedina, Firma genética; Biomarcadores predictivos; Trabectedina, Gene signature; Predictive biomarkers; Trabectedin, Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy., This study was funded by the Spanish Group for Research on Sarcoma (GEIS) and partially by PharmaMar. The authors would like to thank the GEIS data center for data management. The authors also thank the donors and the Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for part of the human specimens used in this study. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

  • Moura, David S.
  • Peña-Chilet, María|||0000-0002-6445-9617
  • Cordero Varela, Juan Antonio|||0000-0002-7373-5433
  • Alvarez-Alegret, Ramiro
  • Agra Pujol, Carolina|||0000-0003-4843-5786
  • Izquierdo, Francisco
  • Ramos, Rafel|||0000-0001-7970-5537
  • Ortega-Medina, Luis
  • Martin-Davila, Francisco
  • Castilla-Ramirez, Carolina
  • Hernandez-Leon, Carmen Nieves
  • Romagosa Perez Portabella, Maria Cleofe|||0000-0002-9478-7320
  • Vaz Salgado, María Ángeles
  • Lavernia, Javier
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Mayodormo-Aranda, Empar
  • Vicioso, Luis
  • Hernández Barceló, José Emilio
  • Rubio-Casadevall, Jordi|||0000-0002-3516-6970
  • de Juan Ferre, Ana|||0000-0002-5852-9068
  • Fiaño-Valverde, María Concepción
  • Hindi, Nadia|||0000-0002-5864-762X
  • Lopez-Alvarez, María
  • Lacerenza, Serena
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Alvarez, Rosa|||0000-0003-0935-8298
  • Valverde Morales, Claudia Maria
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Martín Broto, Javier|||0000-0001-7350-6916
Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel nfix-stat6 gene fusion in solitary fibrous tumor, A case report

  • Moura, David S.
  • Díaz-Martín, Juan|||0000-0002-3985-6434
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Orellana Fernández, Ruth|||0000-0003-1260-7064
  • Sebio, Ana|||0000-0003-3333-2370
  • Mondaza Hernandez, Jose Lucinio|||0000-0002-5642-3796
  • Salguero-Aranda, Carmen
  • Rojo, Federico|||0000-0001-9989-0290
  • Hindi, Nadia|||0000-0002-5864-762X
  • Fletcher, Christopher D.M.
  • Martín Broto, Javier|||0000-0001-7350-6916
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2-STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (sig-nal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2-STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neo-plasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8-STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

  • Hidalgo-Ríos, Samuel
  • Carrillo García, Jaime|||0000-0002-2861-3015
  • Moura, David S.
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Italiano, Antoine|||0000-0002-8540-5351
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Hindi, Nadia|||0000-0002-5864-762X
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Sebio, Ana|||0000-0003-3333-2370
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Le Cesne, Axel
  • Casali, Paolo Giovanni|||0000-0003-4056-8023
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Cruz-Jurado, Josefina|||0000-0001-6398-1641
  • Martín Broto, Javier|||0000-0001-7350-6916
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Moura, David S.
  • Valverde Morales, Claudia Maria
  • Morales, Jose Manuel
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Diaz-Beveridge, Roberto|||0000-0003-3719-7014
  • Luna, Pablo
  • Martínez Marín, Virginia
  • Marcilla, David
  • Arribas, Ivan|||0000-0001-7600-8066
  • Ledesma, Patricio
  • Lopez-Martin, Jose A.|||0000-0001-7530-3207
  • Di Lernia, Davide
  • Zamora, Jorge
  • Hindi, Nadia|||0000-0002-5864-762X
Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best response and BPI, variation of physical function, and analgesic consumption were secondary endpoints. The translational research reported was not a pre-specified secondary outcome. Forty eligible patients started therapy, being 35 radiologically and clinically evaluable. The study achieved its primary endpoint, as 7(20%) patients obtained RECIST partial response, whereas 31(89%) experienced pain reduction of ≥2 points in BPI-SF worst pain. Therapy was well tolerated. With a median follow-up of 30(14-44) months, median 12 and 24-months PFS rates were 91%(CI 95%, 82-100) and 84%(CI 95%, 71-97). For clinical progression, 12 and 24-months PFS rates were 85% (CI 95%, 73-97) and 74% (CI 95%, 58-90) respectively. Short course of nab-paclitaxel is active, safe and achieves quick and durable responses in progressing/symptomatic DF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

REGISTRI, Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

  • Martín Broto, Javier|||0000-0001-7350-6916
  • Valverde Morales, Claudia Maria
  • Hindi, Nadia|||0000-0002-5864-762X
  • Vincenzi, Bruno
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Italiano, Antoine|||0000-0002-8540-5351
  • Lavernia, Javier
  • Vallejo, Ana
  • Tos, Paolo Dei
  • Le Loarer, Francois
  • Gonzalez-Campora, Ricardo
  • Ramos, Rafel|||0000-0001-7970-5537
  • Hernández-Jover, Diana
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Serrano, Cesar|||0000-0003-1416-8739
  • Monteagudo, Maria
  • Letón, Rocio
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Moura, David S.
  • Martin-Ruiz, Marta
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Cruz, Julia
  • Fernandez-Serra, Antonio
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Fumagalli, Elena
  • Martínez Marín, Virginia
Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression of HIF1α high IGFR signaling through the MAPK pathway or BRAF activating mutation, among others. As regorafenib inhibits these signaling pathways, it was hypothesized that it could be more active as upfront therapy in advanced KP-wtGIST. Adult patients with advanced KP-wtGIST after central confirmation by NGS, naïve of systemic treatment for advanced disease, were included in this international phase II trial. Eligible patients received regorafenib 160 mg per day for 21 days every 28 days. The primary endpoint was disease control rate (DCR), according to RECIST 1.1 at 12 weeks by central radiological assessment. From May 2016 to October 2020, 30 patients were identified as KP-wtGIST by Sanger sequencing and 16 were confirmed by central molecular screening with NGS. Finally, 15 were enrolled and received regorafenib. The study was prematurely closed due to the low accrual worsened by COVID outbreak. The DCR at 12 weeks was 86.7% by central assessment. A subset of 60% experienced some tumor shrinkage, with partial responses and stabilization observed in 13% and 87% respectively, by central assessment. SDH-deficient GIST showed better clinical outcome than other KP-wtGIST. Regorafenib activity in KP-wtGIST compares favorably with other tyrosine kinase inhibitors, especially in the SDH-deficient GIST subset and it should be taken into consideration as upfront therapy of advanced KP-wtGIST. ClinicalTrials.gov Identifier: NCT02638766. The online version contains supplementary material available at 10.1186/s12943-023-01832-9.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

  • Moura, David
  • Peña-Chilet, Maria
  • Cordero Varela, Juan Antonio
  • Alvarez Alegret, Ramiro
  • AGRA PUJOL, CAROLINA
  • Izquierdo, Francisco
  • Romagosa, Cleofé
  • Valverde, Claudia María
Signatura genètica; Biomarcadors predictius; Trabectedina, Firma genética; Biomarcadores predictivos; Trabectedina, Gene signature; Predictive biomarkers; Trabectedin, Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy., This study was funded by the Spanish Group for Research on Sarcoma (GEIS) and partially by PharmaMar. The authors would like to thank the GEIS data center for data management. The authors also thank the donors and the Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for part of the human specimens used in this study. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155).